10 results on '"Vollono C"'
Search Results
2. Primary headaches prevalence, characteristics, and healthcare utilization in Italian medical students.
- Author
-
Romozzi M, Trigila V, Cuffaro G, Calabresi P, and Vollono C
- Subjects
- Humans, Female, Male, Prevalence, Cross-Sectional Studies, Young Adult, Italy epidemiology, Adult, Migraine Disorders epidemiology, Surveys and Questionnaires, Headache Disorders, Primary epidemiology, Headache epidemiology, Adolescent, Tension-Type Headache epidemiology, Students, Medical statistics & numerical data, Patient Acceptance of Health Care statistics & numerical data
- Abstract
Background: Among university students, migraine is notably prevalent and is linked to compromised academic performance and daily functioning. Medical students are a particularly vulnerable category due to the demanding nature of their training, as they are often exposed to headache trigger factors. We therefore aimed to determine the prevalence, characteristics, and healthcare-seeking practices of primary headaches among Italian medical students., Methods: We conducted a cross-sectional study among medical students attending the Università Cattolica del Sacro Cuore in Rome who completed a self-administered questionnaire designed following the International Classification of Headache Disorders-3 criteria. The questionnaire assessed sociodemographic and headache features, healthcare utilization, the use of symptomatic and preventive treatment, and headache trigger factors., Results: Five hundred thirty-six students filled out the questionnaire. The lifetime and last-year prevalence of headache in this cohort was 76.7% (n = 411). Among the students surveyed, migraine had a prevalence of 26.9%, probable migraine of 12.9%, and tension-type headache (TTH)/probable TTH of 36.9%. Two hundred and forty-six students (59.8%) reported that their headache worsened after starting university. All students reporting headache had at least one trigger factor. In students fulfilling the criteria for migraine (n = 144), 137 (95.1%) had previously used acute non-prescription treatments, and eight concurrently used a preventive treatment. Thirty-five students fulfilling the criteria for migraine underwent a brain MRI scan (24.3%), 43 performed a neurological evaluation (29.9%), 36 received a diagnosis of migraine (25%), and 20 (13.9%) accessed the emergency room., Discussion: Migraine and TTH are common among medical students in Italy despite low healthcare resource utilization. These results support the need to promote public health policies and strategies in order to reduce the disability and burden associated with primary headaches among medical students., (© 2024. Fondazione Società Italiana di Neurologia.)
- Published
- 2024
- Full Text
- View/download PDF
3. Validation of the Italian version of the Cluster Headache Impact Questionnaire (CHIQ).
- Author
-
Onofri A, Iannone LF, Granato A, Garascia G, Bartole L, Manganotti P, Vollono C, Romozzi M, Sottani C, Calabresi P, Tassorelli C, Sances G, Allena M, De Icco R, De Cesaris F, Burgalassi A, Chiarugi A, Baraldi C, Guerzoni S, Prudenzano MP, Fallacara A, Albanese M, Rainero I, Coppola G, Casalena A, Mampreso E, Pistoia F, Sarchielli P, Morson M, Sacco S, Geppetti P, and Ornello R
- Subjects
- Humans, Quality of Life psychology, Reproducibility of Results, Surveys and Questionnaires, Italy, Psychometrics, Cluster Headache diagnosis, Cluster Headache psychology
- Abstract
Background: The Cluster Headache Impact Questionnaire (CHIQ) is a specific and easy-to-use questionnaire to assess the current impact of cluster headache (CH). The aim of this study was to validate the Italian version of the CHIQ., Methods: We included patients diagnosed with episodic CH (eCH) or chronic CH (cCH) according to the ICHD-3 criteria and included in the "Italian Headache Registry" (RICe). The questionnaire was administered to patients through an electronic form in two sessions: at first visit for validation, and after 7 days for test-retest reliability. For internal consistency, Cronbach's alpha was calculated. Convergent validity of the CHIQ with CH features and the results of questionnaires assessing anxiety, depression, stress, and quality of life was evaluated using Spearman's correlation coefficient., Results: We included 181 patients subdivided in 96 patients with active eCH, 14 with cCH, and 71 with eCH in remission. The 110 patients with either active eCH or cCH were included in the validation cohort; only 24 patients with CH were characterized by a stable attack frequency after 7 days, and were included in the test-retest cohort. Internal consistency of the CHIQ was good with a Cronbach alpha value of 0.891. The CHIQ score showed a significant positive correlation with anxiety, depression, and stress scores, while showing a significant negative correlation with quality-of-life scale scores., Conclusion: Our data show the validity of the Italian version of the CHIQ, which represents a suitable tool for evaluating the social and psychological impact of CH in clinical practice and research., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
4. Correction to: Preventive migraine treatment in mitochondrial diseases: a case report of erenumab efficacy and literature review.
- Author
-
Primiano G, Rollo E, Romozzi M, Calabresi P, Servidei S, and Vollono C
- Published
- 2023
- Full Text
- View/download PDF
5. Preventive migraine treatment in mitochondrial diseases: a case report of erenumab efficacy and literature review.
- Author
-
Primiano G, Rollo E, Romozzi M, Calabresi P, Servidei S, and Vollono C
- Subjects
- Humans, Calcitonin Gene-Related Peptide Receptor Antagonists therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Migraine Disorders drug therapy, Migraine Disorders prevention & control, Mitochondrial Diseases drug therapy, Mitochondrial Diseases genetics
- Abstract
Migraine is a common condition in mitochondrial diseases, with a higher prevalence than in the general population. Although several clinical studies support the hypothesis that mitochondrial dysfunction plays a central role in the pathophysiology of migraine, currently there are few data in the literature regarding the efficacy and safety of drugs for the treatment and prophylaxis for this condition in patients with primary mitochondrial disorders. We report a 37-year-old woman affected by mitochondrial disease with progressive external ophthalmoplegia phenotype (PEO) associated with POLG mutation effectively treated with erenumab, in the absence of side effects. Monoclonal antibodies against the calcitonin gene-related peptide (CGRP) or against its receptor are innovative and specific therapies for migraine prophylaxis. This class of drugs is particularly suitable for subjects, such as those suffering from genetically determined mitochondrial dysfunction, in which pharmacological management can represent a challenge due to the nature of these neurogenetic disorders and/or the frequently associated comorbidities., (© 2022. Fondazione Società Italiana di Neurologia.)
- Published
- 2022
- Full Text
- View/download PDF
6. Impact of COVID-19 vaccine on epilepsy in adult subjects: an Italian multicentric experience.
- Author
-
Romozzi M, Rollo E, Quintieri P, Dono F, Evangelista G, Consoli S, Veleno L, Anzellotti F, Calvello C, Costa C, Servidei S, Calabresi P, and Vollono C
- Subjects
- Adult, Aged, Anticonvulsants therapeutic use, Humans, Middle Aged, SARS-CoV-2, Vaccines therapeutic use, COVID-19 complications, COVID-19 prevention & control, COVID-19 Vaccines adverse effects, Epilepsy drug therapy
- Abstract
Objectives: To investigate the safety and tolerability of COVID-19 vaccines in people with epilepsy (PwE)., Methods: In this multicentric observational cohort study, we recruited adult patients (age > 18 years old) with epilepsy who attended the Outpatient Epilepsy Clinic from 1st July to 30th October 2021. We administered to the patients a structured questionnaire and interview on demographic and epilepsy characteristics, current treatment, previous SARS-CoV-2 infection, vaccine characteristics, post-vaccine seizure relapse, other side effect, variation of sleep habits, caffeine, or alcohol intake. Seizure frequency worsening was defined as a ratio between mean monthly frequency post-vaccination and mean monthly frequency pre-vaccination superior to 1. Patients were categorized in two groups: patients with seizure frequency worsening (WORSE) and patients with seizure stability (STABLE)., Results: A total of 358 people participated with a mean age of 47.46 ± 19.04. Focal seizure (79.1%), generalized epilepsy (20.4%), and unknown types of epilepsy (0.5%) were detected among participants. In total, 31 (8.7%) people expressed that they were not willing to receive a COVID-19 vaccine; 302 patients (92.35%) did not experience an increase in the seizure frequency (STABLE-group) whereas 25 patients (7.65%) had a seizure worsening (WORSE-group). Post-vaccine seizures occurred mainly in the 7 days following the administration of the vaccine. Patients in the WORSE-group were treated with a mean higher number of anti-seizure medication (ASMs) (p = 0.003) and had a higher pre-vaccine seizure frequency (p = 0.009) compared with patients in the STABLE-group. Drug-resistant epilepsy was also associated with seizure worsening (p = 0.01). One-year pre-vaccination seizure frequency pattern demonstrated that patients in the WORSE-group had a higher frequency pattern (p < 0.001). Multivariate analysis of the vaccinated group showed that only the seizure frequency pattern (confidence interval [CI] = 1.257-2.028; p < 0.001) was significantly associated with seizure worsening., Conclusion: In our cohort of vaccinated PwE, only a little percentage had a transient short-term increase of seizure frequency. The present study demonstrates that COVID-19 vaccines have a good safety and tolerability profile in the short term in PwE., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
7. Heart rate variability and delirium in acute non-cardioembolic stroke: a prospective, cross-sectional, cohort study.
- Author
-
Rollo E, Marotta J, Callea A, Brunetti V, Vollono C, Scala I, Imperatori C, Frisullo G, Broccolini A, and Della Marca G
- Subjects
- Adolescent, Cohort Studies, Cross-Sectional Studies, Heart Rate, Humans, Intensive Care Units, Prospective Studies, Delirium diagnosis, Delirium etiology
- Abstract
Objectives: Delirium is an acute fluctuating disorder of attention and awareness. It is associated with autonomic dysfunction and increased mortality. The primary endpoint of our study was to measure autonomic activity in acute stroke patients, by means of heart rate variability analysis, in order to identify autonomic modifications that can predispose to delirium., Methods: Patients were consecutively enrolled from the stroke unit. Inclusion criteria were age ≥ 18 years and diagnosis of stroke with onset within the previous 72 h confirmed by neuroimaging. Exclusion criteria were atrial fibrillation, congestive heart failure, and conditions requiring intensive care unit. Patients were evaluated by means of Richmond Agitation Sedation Scale (RASS) and Confusion Assessment Method-Intensive Care Unit (CAM-ICU) at baseline, after 72 h, or when symptoms suggesting delirium occurred. For each patient, ECG was recorded at baseline assessment and HRV analysis was conducted on five consecutive minutes of artifact-free ECG traces., Results: Fifty-six ECGs were available for analysis. During the study period, 11 patients developed delirium. Patients with and without delirium did not differ for sex, age, severity of stroke, and comorbidities. The delirium group had greater standard deviation of the heart rate (DLR - :9.16 ± 8.28; DLR + : 14.36 ± 5.55; p = 0.026) and lower power spectral density of the HF component (DLR - : 38.23 ± 19.23 n.u.; DLR + : 25.75 ± 8.77 n.u.; p = 0.031)., Conclusions: Acute non-cardioembolic stroke patients with increased variability of heart rate and decreased vagal control are at risk for delirium., (© 2021. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
8. A voxel-based lesion symptom mapping analysis of chronic pain in multiple sclerosis.
- Author
-
Plantone D, Vollono C, Pardini M, Primiano G, Myftari V, Vitetta F, Sola P, Mirabella M, and Ferraro D
- Subjects
- Aged, Humans, Magnetic Resonance Imaging, Middle Aged, Prefrontal Cortex, Chronic Pain diagnostic imaging, Chronic Pain etiology, Multiple Sclerosis complications, Multiple Sclerosis diagnostic imaging
- Abstract
Background: Pain is one of the most disabling symptoms in multiple sclerosis. Chronic pain in multiple sclerosis is often neuropathic in nature, although a clear-cut distinction with nociceptive pain is not easy., Objective: The aim of our study was to analyze the MRIs of multiple sclerosis patients with chronic pain in order to explore possible associations with lesion sites, on a voxel-by-voxel basis., Materials and Methods: We enrolled patients aged > 18 years with multiple sclerosis in accordance with the 2010 McDonald criteria. Patients meeting criteria for persistent pain (frequent or constant pain lasting > 3 months) were included in the "pain group". The other patients were included in the "no pain group". We outlined lesions on FLAIR MRI scans using a semi-automated edge finding tool. To detect the association between lesion localization and persistent pain, images were analysed with the voxel-based lesion symptom mapping methods implemented in the (nonparametric mapping software included into the MRIcron., Results: We enrolled 208 MS patients (140 F, mean age 55.2 ± 9.4 years; 176 RR, 28 progressive MS; mean EDSS 2.0 + 2.0). Pain group included 96 patients and no pain group 112 patients. Lesions of the right dorsolateral prefrontal area were significantly more prevalent in patients without pain, whereas periventricular posterior lesions were significantly more prevalent in patients with persistent pain., Conclusion: Our data suggest a role of the right dorsolateral prefrontal cortex in the modulation of pain perception and in the occurrence of chronic pain in MS patients. Our data also support a hemispheric asymmetry in pain perception and modulation.
- Published
- 2021
- Full Text
- View/download PDF
9. Systematic assessment and characterization of chronic pain in multiple sclerosis patients.
- Author
-
Ferraro D, Plantone D, Morselli F, Dallari G, Simone AM, Vitetta F, Sola P, Primiano G, Nociti V, Pardini M, Mirabella M, and Vollono C
- Subjects
- Analgesics therapeutic use, Chronic Pain epidemiology, Chronic Pain physiopathology, Cross-Sectional Studies, Disability Evaluation, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multiple Sclerosis diagnosis, Multiple Sclerosis epidemiology, Multiple Sclerosis physiopathology, Neuralgia diagnosis, Neuralgia epidemiology, Neuralgia etiology, Neuralgia physiopathology, Pain Management, Pain Measurement methods, Prevalence, Psychiatric Status Rating Scales, Chronic Pain diagnosis, Chronic Pain etiology, Multiple Sclerosis complications
- Abstract
Pain is one of the most disabling clinical symptoms in patients with multiple sclerosis (MS). Several studies have already assessed the prevalence of pain in MS patients, reporting variable results, probably due to methodological differences. The aim of this single-centre cross-sectional study was to define the prevalence and characteristics of chronic pain in a population of MS patients using validated tools, and to analyse these data in relation to demographic and clinical features, including disease duration and disability (EDSS and its single functional system scores). Of 397 enrolled patients, 23 were excluded due to a Beck's Depression Inventory Score > 19. In the remaining 374 patients, the overall prevalence of chronic pain was 52.1%, most frequently affecting the lower limbs (36.9%). Neuropathic pain was the most frequent type of chronic pain (89 patients, overall prevalence of 23.7%) and was associated with a sensory functional system involvement. Pain intensity was significantly higher in patients with neuropathic pain as opposed to patients with non-neuropathic pain. Patients with chronic pain and, in particular, patients with neuropathic pain had significantly higher EDSS scores than those without pain. Only 24% of patients with chronic pain and 33% of patients with neuropathic pain were on a specific long-lasting treatment for pain. The present study supports the routine assessment of neuropathic pain in MS patients, especially in those with a sensory functional system involvement, in order to avoid underdiagnosing and undertreating a potentially disabling condition.
- Published
- 2018
- Full Text
- View/download PDF
10. Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study.
- Author
-
Mei D, Capuano A, Vollono C, Evangelista M, Ferraro D, Tonali P, and Di Trapani G
- Subjects
- Adult, Double-Blind Method, Female, Fructose adverse effects, Humans, Male, Middle Aged, Migraine Disorders epidemiology, Neuroprotective Agents adverse effects, Topiramate, Fructose analogs & derivatives, Fructose therapeutic use, Migraine Disorders prevention & control, Neuroprotective Agents therapeutic use
- Abstract
The objectives of this paper are to evaluate the efficacy and tolerability of topiramate, given at the dose of 100 mg/day, in the prophylactic treatment of migraine. The hypothesis that migraine is the result of a condition of neuronal hyperexcitability and the quest for drugs that are able to limit the number of crises justifies the attempt to utilise the new antiepileptic drugs in the prophylaxis of this pathology, which is so important due to its high prevalence and due to the high disability it causes. The study was randomised double-blind versus placebo, lasting 16 weeks, and was preceded by a run-in period of 4 weeks. One hundred and fifteen patients were randomly allocated to treatment with topiramate (TPM) or placebo: 35 patients completed the study in the TPM group and 37 patients in the placebo group. At the end of the double-blind phase of study, in the TPM group, we recorded a significant reduction in the frequency of migraine crises (from 5.26 at baseline to 2.60 in the last 4 weeks), a significant reduction in the quantity of symptomatic drugs taken as compared to the placebo control group (from 6.17+/-1.80 SD to 2.57+/-0.80) and a significant downward trend in the number of days of disability over the 16-week period of therapy. In the TPM group, side effects were transient and well tolerated. TPM has thus proven its efficacy and tolerability in the prophylaxis of migraine.
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.